scispace - formally typeset
Search or ask a question
Author

Josep M. Antó

Other affiliations: University of Rochester, Centra, Services Hospital  ...read more
Bio: Josep M. Antó is an academic researcher from Pompeu Fabra University. The author has contributed to research in topics: Asthma & Population. The author has an hindex of 100, co-authored 493 publications receiving 38663 citations. Previous affiliations of Josep M. Antó include University of Rochester & Centra.
Topics: Asthma, Population, COPD, Atopy, Allergy


Papers
More filters
Journal ArticleDOI
Jeffrey D. Stanaway1, Ashkan Afshin1, Emmanuela Gakidou1, Stephen S Lim1  +1050 moreInstitutions (346)
TL;DR: This study estimated levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs) by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017 and explored the relationship between development and risk exposure.

2,910 citations

Journal ArticleDOI
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of risk factor exposure and attributable burden of disease as discussed by the authors.

1,755 citations

Journal ArticleDOI
Joan B. Soriano1, Joan B. Soriano2, Amanuel Alemu Abajobir3, Kalkidan Hassen Abate4, Semaw Ferede Abera, Anurag Agrawal, Muktar Beshir Ahmed4, Amani Nidhal Aichour, Ibtihel Aichour, Miloud Taki Eddine Aichour, Khurshid Alam, Noore Alam, Juma Alkaabi5, Fatma Al-Maskari5, Nelson Alvis-Guzman6, Alemayehu Amberbir, Yaw Ampem Amoako, Mustafa Geleto Ansha, Josep M. Antó, Hamid Asayesh7, Tesfay Mehari Atey8, Euripide Frinel G Arthur Avokpaho, Aleksandra Barac9, Sanjay Basu10, Neeraj Bedi, Isabela M. Benseñor11, Adugnaw Berhane12, Addisu Shunu Beyene13, Addisu Shunu Beyene14, Zulfiqar A Bhutta, Stan Biryukov, Dube Jara Boneya15, Michael Brauer, David O. Carpenter16, David O. Carpenter17, Daniel C Casey, Devasahayam J. Christopher18, Lalit Dandona, Rakhi Dandona, Samath D Dharmaratne19, Huyen Phuc Do, Florian Fischer20, TT Gebrehiwot13, TT Gebrehiwot21, TT Gebrehiwot22, Ayele Geleto13, Ayele Geleto21, Ayele Geleto22, Aloke Gopal Ghoshal, Richard F. Gillum23, Ibrahim Abdelmageem Mohamed Ginawi, Vipin Gupta24, Simon I. Hay, Mohammad Taghi Hedayati25, Nobuyuki Horita26, Nobuyuki Horita27, H. Dean Hosgood28, Mihajlo Jakovljevic, Spencer L. James, Jost B. Jonas, Amir Kasaeian, Yousef Khader, Ibrahim A Khalil, Ejaz Ahmad Khan, Young-Ho Khang, Jagdish Khubchandani, Luke D. Knibbs, Soewarta Kosen, Parvaiz A Koul, G Anil Kumar, Cheru Tesema Leshargie, Xiaofeng Liang, Hassan Magdy Abd El Razek, Azeem Majeed, Deborah Carvalho Malta, Treh Manhertz, Neal Marquez, Alem Mehari, George A. Mensah, Ted R. Miller, Karzan Abdulmuhsin Mohammad, Kedir Endris Mohammed, Shafiu Mohammed, Ali H. Mokdad, Mohsen Naghavi, Cuong Tat Nguyen, Grant Nguyen, Quyen Nguyen, Trang Huyen Nguyen, Dina Nur Anggraini Ningrum, Vuong Minh Nong, Jennifer Ifeoma Obi, Yewande E Odeyemi, Felix Akpojene Ogbo, Eyal Oren, Padukudru Anand Mahesh, Eun-Kee Park, George C Patton, Katherine R. Paulson, Mostafa Qorbani, Reginald Quansah, Anwar Rafay, Mohammad Hifz Ur Rahman, Rajesh Kumar Rai, Salman Rawaf, Nik Reinig, Saeid Safiri, Rodrigo Sarmiento-Suarez, Benn Sartorius, Miloje Savic, Monika Sawhney, Mika Shigematsu, Mari Smith, Fentaw Tadese, George D. Thurston, Roman Topor-Madry, Bach Xuan Tran, Kingsley N. Ukwaja, Job F M van Boven, Vasiliy Victorovich Vlassov, Stein Emil Vollset, Xia Wan, Andrea Werdecker, Sarah Wulf Hanson, Yuichiro Yano, Hassen Hamid Yimam, Naohiro Yonemoto, Chuanhua Yu, Zoubida Zaidi, Maysaa El Sayed Zaki, Alan D. Lopez, Christopher J L Murray, Theo Vos 
TL;DR: The GBD study provides annual updates on estimates of deaths, prevalence, and disability-adjusted life years (DALYs), a summary measure of fatal and non-fatal disease outcomes, for over 300 diseases and injuries, for 188 countries from 1990 to the most recent year.

1,601 citations

Journal ArticleDOI
01 Sep 2006-Thorax
TL;DR: The recommendation that COPD patients be encouraged to maintain or increase their levels of regular physical activity should be considered in future COPD guidelines, since it is likely to result in a relevant public health benefit.
Abstract: Background: Information about the influence of regular physical activity on the course of chronic obstructive pulmonary disease (COPD) is scarce. A study was undertaken to examine the association between regular physical activity and both hospital admissions for COPD and all-cause and specific mortality in COPD subjects. Methods: From a population-based sample recruited in Copenhagen in 1981–3 and 1991–4, 2386 individuals with COPD (according to lung function tests) were identified and followed until 2000. Self-reported regular physical activity at baseline was classified into four categories (very low, low, moderate, and high). Dates and causes of hospital admissions and mortality were obtained from Danish registers. Adjusted associations between physical activity and hospital admissions for COPD and mortality were obtained using negative binomial and Cox regression models, respectively. Results: After adjustment for relevant confounders, subjects reporting low, moderate or high physical activity had a lower risk of hospital admission for COPD during the follow up period than those who reported very low physical activity (incidence rate ratio 0.72, 95% confidence interval (CI) 0.53 to 0.97). Low, moderate and high levels of regular physical activity were associated with an adjusted lower risk of all-cause mortality (hazard ratio (HR) 0.76, 95% CI 0.65 to 0.90) and respiratory mortality (HR 0.70, 95% CI 0.48 to 1.02). No effect modification was found for sex, age group, COPD severity, or a background of ischaemic heart disease. Conclusions: Subjects with COPD who perform some level of regular physical activity have a lower risk of both COPD admissions and mortality. The recommendation that COPD patients be encouraged to maintain or increase their levels of regular physical activity should be considered in future COPD guidelines, since it is likely to result in a relevant public health benefit.

1,002 citations

Journal ArticleDOI
Joan B. Soriano1, Parkes J Kendrick2, Katherine R. Paulson2, Vinay Gupta2  +311 moreInstitutions (178)
TL;DR: It is shown that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990.

829 citations


Cited by
More filters
28 Jul 2005
TL;DR: PfPMP1)与感染红细胞、树突状组胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作�ly.
Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1(PfPMP1)与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员,通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

18,940 citations

Journal ArticleDOI
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
Abstract: Chronic obstructive pulmonary disease (COPD) remains a major public health problem. It is the fourth leading cause of chronic morbidity and mortality in the United States, and is projected to rank fifth in 2020 in burden of disease worldwide, according to a study published by the World Bank/World Health Organization. Yet, COPD remains relatively unknown or ignored by the public as well as public health and government officials. In 1998, in an effort to bring more attention to COPD, its management, and its prevention, a committed group of scientists encouraged the U.S. National Heart, Lung, and Blood Institute and the World Health Organization to form the Global Initiative for Chronic Obstructive Lung Disease (GOLD). Among the important objectives of GOLD are to increase awareness of COPD and to help the millions of people who suffer from this disease and die prematurely of it or its complications. The first step in the GOLD program was to prepare a consensus report, Global Strategy for the Diagnosis, Management, and Prevention of COPD, published in 2001. The present, newly revised document follows the same format as the original consensus report, but has been updated to reflect the many publications on COPD that have appeared. GOLD national leaders, a network of international experts, have initiated investigations of the causes and prevalence of COPD in their countries, and developed innovative approaches for the dissemination and implementation of COPD management guidelines. We appreciate the enormous amount of work the GOLD national leaders have done on behalf of their patients with COPD. Despite the achievements in the 5 years since the GOLD report was originally published, considerable additional work is ahead of us if we are to control this major public health problem. The GOLD initiative will continue to bring COPD to the attention of governments, public health officials, health care workers, and the general public, but a concerted effort by all involved in health care will be necessary.

17,023 citations

01 Jan 2014
TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Abstract: XI. STRATEGIES FOR IMPROVING DIABETES CARE D iabetes is a chronic illness that requires continuing medical care and patient self-management education to prevent acute complications and to reduce the risk of long-term complications. Diabetes care is complex and requires that many issues, beyond glycemic control, be addressed. A large body of evidence exists that supports a range of interventions to improve diabetes outcomes. These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care. While individual preferences, comorbidities, and other patient factors may require modification of goals, targets that are desirable for most patients with diabetes are provided. These standards are not intended to preclude more extensive evaluation and management of the patient by other specialists as needed. For more detailed information, refer to Bode (Ed.): Medical Management of Type 1 Diabetes (1), Burant (Ed): Medical Management of Type 2 Diabetes (2), and Klingensmith (Ed): Intensive Diabetes Management (3). The recommendations included are diagnostic and therapeutic actions that are known or believed to favorably affect health outcomes of patients with diabetes. A grading system (Table 1), developed by the American Diabetes Association (ADA) and modeled after existing methods, was utilized to clarify and codify the evidence that forms the basis for the recommendations. The level of evidence that supports each recommendation is listed after each recommendation using the letters A, B, C, or E.

9,618 citations

Journal ArticleDOI
Stephen S Lim1, Theo Vos, Abraham D. Flaxman1, Goodarz Danaei2  +207 moreInstitutions (92)
TL;DR: In this paper, the authors estimated deaths and disability-adjusted life years (DALYs; sum of years lived with disability [YLD] and years of life lost [YLL]) attributable to the independent effects of 67 risk factors and clusters of risk factors for 21 regions in 1990 and 2010.

9,324 citations